Form 4: GoodRx Director Scott Wagner's Equity Vesting

GoodRx Holdings, Inc. Director Scott Wagner acquired 31,394 shares of Class A Common Stock following the vesting of deferred stock units on January 21, 2026.

Summary

• Scott Wagner, a Director of GoodRx Holdings, Inc. (GDRX), reported a transaction on January 21, 2026.
• The transaction involved the vesting of 31,394 deferred stock units (DSUs).
• These vested DSUs resulted in the acquisition of 31,394 shares of Class A Common Stock.
• Following this transaction, Wagner beneficially owns 216,663 shares of Class A Common Stock directly.
• Wagner also beneficially owns 62,788 derivative securities in the form of Deferred Stock Units.
• The deferred stock unit award vested as to one-third of the shares underlying the award.

Sentiment

Score: 6

Explanation: The filing reports a routine, expected vesting of equity for a director, which is generally a neutral to slightly positive event as it aligns management interests with shareholders. No unexpected positive or negative news is present.

Positives

• Vesting of 31,394 deferred stock units into Class A Common Stock for Director Scott Wagner, indicating continued equity alignment with shareholder interests.
• The transaction is part of a pre-existing compensation plan, demonstrating a structured approach to executive incentives.

Future Outlook

The remaining deferred stock units will settle on the earliest of December 31, 2030, Separation from Service, a Change in Control, death, or Disability, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minor positive impact due to increased alignment of a director's interests with shareholders through equity ownership.

Next Steps

• The remaining deferred stock units will settle upon the occurrence of specific future events, including December 31, 2030, separation from service, change in control, death, or disability.

Key Dates

Keywords

GoodRx, GDRX, Scott Wagner, Director, Form 4, Insider Trading, Stock Vesting, Deferred Stock Units, Equity Compensation, Class A Common Stock